Lilly GMP “Culture Change” Will Address Compliance Issues, Firm Tells FDA
Executive Summary
Lilly is seeking to "affect cultural change" in its approach to GMP compliance, the company assured FDA in a response to the most recent FDA-483 manufacturing report for Forteo and Zyprexa IM